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Minimum Clinical Recommendations for diagnosis, treatment
and follow-up of malignant pleural mesothelioma
Incidence
. Malignant pleural mesothelioma (MPM) is a rare tumor.
The incidence is 1.25/100 000 in UK and 1.1/100 000 in
Germany. Within the next 20 years the incidence is esti-
mated to double. Asbestos is a well established etiological
factor for MPM, with occupational exposure in 70–80% of
those affected.
Diagnosis
. Patients typically present with chest pain or increasing
shortness of breath. The diagnosis is usually suggested by
imaging studies (unilateral pleural mass; pleural effusion).
Occupational history must be obtained.
. Cytological examination of the effusion or pleural biopsy
can be diagnostic, but often shows equivocal results. Video-
assisted thoracoscopy or open pleural biopsy may be necess-
ary to provide sufficient material. There are three main his-
tological types (epithelial, sarcomatous, and mixed) with
about 60% being epithelial.
Staging and risk assessment
. Staging includes complete history, physical examination,
and chest X-ray. If local therapy is being considered a CT
scan of the chest should be obtained. Accurate initial sta-
ging is important as this will provide both prognostic infor-
mation and suggest the most appropriate therapeutic
options. The new international staging system for MPM
emphasizes the extent of disease in a traditional TNM sys-
tem and stratifies patients into similar prognostic categories
(see Table 1).
. The Cancer and Leukemia Group B (CALGB) and the
EORTC prognostic scores may be used. They include per-
formance status, age, histological type, weight loss, and
white blood count.
. MPM rarely metastasize to distant sites but most patients
present with locally advanced disease.
Treatment
Surgery
. A variety of surgical procedures have been tried with vari-
able success.
. Extra-pleural pneumonectomy with excision of the dia-
phragm and the pericardium en bloc has the potential of
complete removal of the tumor. This approach is generally
combined with chemotherapy and/or radiotherapy and
should only be attempted by expert surgeons and chest
oncology teams [III, A].
. Palliative local procedures include parietal pleurectomy,
decortication or pleurodesis.
Radiotherapy
. The use of conventional radiotherapy has been limited
because it is impossible to avoid high-dose irradiation of the
underlying lung. Conventional dose can be delivered in a
palliative attempt. Modern radiotherapy techniques can deli-
ver high dose radiotherapy with curative intent after extra-
pleural pneumonectomy. Prophylactic radiotherapy has been
shown to reduce the incidence of port metastases [II, A].
Chemotherapy
. Platinum analogues, doxorubicin and several antimetabolites
(methotrexate, etatrexate, raltitrexate, pemetrexed) have
shown modest single agent activity [III, B].
. Better symptom improvement may be obtained with gemci-
tabine in combination with cisplatin [III, A].
. The combination of pemetrexed and cisplatin improved sur-
vival and quality of life in comparison to cisplatin alone in
a randomized trial [II, A].
. Available date indicate a similar management for extra-
pleural malignant mesothelioma [IV, A].
Follow-up
. Follow-up consists of clinical evaluation with particular
attention to symptoms and chest-CT as needed.
Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
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Table 1.
Stage TNM Comments
Ia T1a N0 M0 Primary tumor limited to ipsilateral parietal pleura
Ib T1b N0 M0 As stage Ia plus focal involvement of visceral pleura
II T2 N0 M0 As stage Ia or Ib plus confluent involvement of diaphragm or visceral pleura or involvement of the lung
III any T3 M0, any N1 M0,
any N2 M0
Locally advanced, potentially resectable tumor; ipsilateral, bronchopulmonary or hilar
lymph node involvement; subcarinal or ipsilateral mediastinal lymph node involvement
IV any T4, any N3, any M1 Locally advanced technically unresectable tumor; contralateral mediastinal, internal mammary,
and ipsilateral or contralateral supraclavicular lymph node involvement; distant metastases
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